Table 4.

Newly initiated trials combining bevacizumab with radiotherapy (2012–2017)

Trial	Phase	Diseasea	Schedulingb	Radiotherapy regimec	Chemotherapy	Statusd
NCT01730950	II	GBM	Conc	IMRT, 3D-CRT, or proton beam RT 5 days a week for 2 weeks	None	2
NCT01746238	I	STS	Conc	6 weeks, 5 days a week	Doxorubicin	3
NCT02313272	I	GBM	Conc	Hypofractionated SRT	Pembrolizumab	3
NCT01871363	II	RC	Conc	25 × 2 Gy	Capecitabine	5
NCT01743950	II	GBM	Conc	27 × 2 Gy (PRDR)	None	3
NCT01569984	II	mCRC	Neo	Up to 60 Gy in six fractions, alternating weekdays for 2 weeks	None	1
NCT02185352	II	BM in BC	Neo	WBRT	Etoposide, cisplatin	3
NCT01580969	Ib/II	Glioma	Conc	Individually determined	Minocycline	3
NCT01588431	II	HNSCC	Neo/conc	5 weeks, 70 Gy	Docetaxel, cetuximab, cisplatin	2
NCT01818973	II	RC	Neo/conc	5 weeks, 50 Gy	Capecitabine + oxaliplatin	3
NCT01554059	II	RC	Neo/conc	5 weeks, 50 Gy	5-FU, oxaliplatin	1
NCT02812641	II	EC	Conc	4 weeks, 40 Gy	Cisplatin, 5-FU	3
NCT02672995	I	BM	Conc	Three fractions, 18–27 Gy	None	3

^aDisease: GBM glioblastoma, STS soft tissue sarcoma, RC rectal cancer, mCRC metastatic colorectal cancer, BM brain metastasis, BC breast cancer, HNSCC head and neck squamous cell cancer, EC esophageal cancer

^bScheduling: scheduling of angiostatic drug to radiotherapy neo neoadjuvant, conc concurrent, adj adjuvant

^cRadiotherapy: radiation is applied at a frequency of 5 days/week unless indicated otherwise. When the dose applied is unknown, this is indicated with × Gy

^dStatus: 1 = completed; 2 = active, not recruiting; 3 = recruiting; 4 = terminated/withdrawn; 5 = unknown